Supplements and Featured Publications
Milestones in Medicine: Updates in AML
Volume 1
Issue 1

Dr. Shallis on the Investigation of Uproleselan in AML

Rory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.

Rory Shallis, MD, assistant professor of Medicine, Hematology, Yale School of Medicine, discusses the investigation of uproleselan (GMI-1271) in acute myeloid leukemia (AML).

Uproleselan is a small molecule, E-selectin inhibitor that has been shown to disrupt the microenvironmental protection of leukemia cells, according to Shallis. The agent mobilizes those cells into circulation and improves responses observed with traditional chemotherapy options, Shallis says. Notably, the efficacy of the agent does not appear to be dependent on a specific set of genetic or molecular profiles, Shallis adds. Rather, efficacy with uproleselan appears to be disease biology agnostic, according to Shallis.

This agent has been evaluated in combination with multiagent chemotherapy as part of a phase 1/2 trial (NCT02306291). The combination elicited a remission rate of 41% in the salvage cohort, with a complete response rate of 35%, Shallis adds. The data indirectly mirrored historical expectations of other treatments for patients in this setting, but there were no clear differences in time to or quality of count recovery, Shallis explains. 

The addition of uproleselan to chemotherapy resulted in low rates of toxicity, with lower-than-expected rates of mucositis were observed, Shallis notes; this is attributed to the role that E-selectin expression has on inflammation. According to Shallis, this may be relevant for older patients with AML who have other comorbidities that may make the risk of mucositis more problematic, Shallis concludes.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD